Covidien of Mansfield, MA, has signed a license agreement to develop a radiolabeled molecular imaging agent to evaluate the efficacy of cancer treatments with NewSouth Innovations, the technology transfer unit of the University of New South Wales (UNSW) in Sydney, Australia.
Under the exclusive, worldwide agreement, Covidien's imaging solutions business in St. Louis has product development and commercialization rights for the apoptosis technology. The technology is based on small molecules designed to bind to cancer cells undergoing apoptosis, or the process of cell death, as a result of chemotherapy treatment.
Covidien said the early-stage apoptosis detection technology could take many years to develop, but it has the potential for broad application across a wide array of solid tumor cancers.
By AuntMinnie.com staff writers
October 8, 2007
Related Reading
Covidien emerges from Tyco's shadow with R&D emphasis, August 20, 2007
Covidien makes debut as Tyco spinoff, July 5, 2007
E-Z-EM to fight Tyco lawsuit, July 2, 2007
Tyco Healthcare names Wright as pharma/imaging president, March 20, 2007
Tyco hit with lawsuit over gadolinium reaction, March 19, 2007
Copyright © 2007 AuntMinnie.com
